HK Stock Market Move | ANTENGENE-B(06996) rose more than 3% during trading hours. The adjusted annual loss for the year 2025 narrowed by 23.5% compared to the previous year.
Dakini Pharmaceutical-B (06996) rose more than 3% during trading hours, as of the time of writing, it has risen by 3.57%, reaching 4.06 Hong Kong dollars, with a turnover of 67.949 million Hong Kong dollars.
ANTENGENE-B (06996) rose by more than 3% in midday trading, up 3.57% at the time of writing to 4.06 Hong Kong dollars, with a trading volume of 6.7949 million Hong Kong dollars.
In terms of news, recently, ANTENGENE-B released its annual performance for the year ending December 31, 2025. The group achieved revenue of 105 million yuan (same unit), an increase of 14.56% year-on-year; research and development expenses were 169 million yuan, a decrease of 34.69% year-on-year; net loss for the year was 239 million yuan, a decrease of 25.10% year-on-year; adjusted net loss for the year was 233 million yuan, a decrease of 23.50% year-on-year; loss per share was 0.38 yuan.
The announcement stated that the increase in revenue was mainly due to accelerating contributions from mainland China, benefiting from the steady increase in market penetration and continuous deepening of commercial cooperation.
Related Articles
UBS: Henderson Land (00012) core profit and dividend payment in line with expectations, target price of 30.5 Hong Kong dollars.
UBS: WuXi AppTec (02359) net profit for the last quarter slightly exceeded expectations, raising target price to HK$154.1.
HK Stock Market Move | Sinopharm (01099) fell nearly 5%. Last year, net profit increased by 1.5% year-on-year. Citigroup slightly lowered the company's target price.
UBS: Henderson Land (00012) core profit and dividend payment in line with expectations, target price of 30.5 Hong Kong dollars.
UBS: WuXi AppTec (02359) net profit for the last quarter slightly exceeded expectations, raising target price to HK$154.1.
HK Stock Market Move | Sinopharm (01099) fell nearly 5%. Last year, net profit increased by 1.5% year-on-year. Citigroup slightly lowered the company's target price.
